Reviewer’s report

Title: Effect of low dose naloxone on the immune system function of a patient undergoing videoassisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia — a randomized controlled trial.

Version: 0 Date: 29 Sep 2019

Reviewer: Jose Navas

Reviewer's report:

The authors present a small prospective, single center, randomized controlled trial testing whether perioperative low-dose naloxone in patients undergoing VATS for suspected lung cancer is associated to better immunologic profile versus a control group without naloxone perioperatively.

Overall, the manuscript is well written, easy to understand, follow and reproduce. Introduces a very important concept depicting the impact of perioperative anesthetic techniques in cancer recurrence and only few issues need to be addressed as following:

1. Initially the abstract depicts that the 2 groups have 35 patients, when in reality one of the dropped out due to loss in follow-up. I think it should be stated in the abstract the number of patients that actually underwent the analysis (35 and 34).

2. Page 4, Method section, ASA status: I just wanted further clarification, how exactly someone who has a suspected lesion for lung cancer, in his/her mid-50s, could be classified as ASA 1? Even the ASA 2. The ASA clearly states that ASA 2 is "mild lung disease". Please provide further clarification, seems to be that this should have been ASA 2s and 3s.

3. Page 5, Method section, second paragraph, line 16: Please replace Sauteralgyl, for its generic version, Meperidine.

4. Page 5, Method section, last paragraph: Regarding the nausea and vomiting score, please provide a citation to support this scoring system or if you introduced this score in this study please provide details regarding the validation of this scale.

5. Page 7, Result section, paragraph 2: Please fix "figure 3" spelling.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal